title: Toxocara canis meningomyelitis.
authors.forename: Valérie
authors.initials: V
authors.lastname: Dauriac-Le Masson
authors.forename: Florence
authors.initials: F
authors.lastname: Chochon
authors.forename: Sophie
authors.initials: S
authors.lastname: Demeret
authors.forename: Charles
authors.initials: C
authors.lastname: Pierrot-Deseilligny
mesh_terms: D000328:Adult; D000818:Animals; D000909:Antibodies, Helminth / Q000134:cerebrospinal fluid; D000969:Antinematodal Agents / Q000009:adverse effects / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D004802:Eosinophilia / Q000134:cerebrospinal fluid / Q000469:parasitology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008463:Mebendazole / Q000009:adverse effects / Q000627:therapeutic use; D008581:Meningitis / Q000188:drug therapy / Q000469:parasitology*; D009187:Myelitis / Q000188:drug therapy / Q000469:parasitology*; D011379:Prognosis; D013997:Time Factors; D017166:Toxocara canis; D014120:Toxocariasis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000909:Antibodies, Helminth; D000969:Antinematodal Agents; D008463:Mebendazole